Radiosurgery for brain metastases: is whole brain radiotherapy necessary?

Sneed, Penny K.; Lamborn, Kathleen R.; Forstner, Julie M.; McDermott, Michael W.; Chang, Susan M.; Park, Elaine; Gutin, Philip H.; Phillips, Theodore L.; Wara, William M.; Larson, David A.

doi:10.1016/s0360-3016(98)00447-7

Cited by 385 publications

(195 citation statements)

References 23 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…After the risk of bias and quality assessment, all the included studies showed high qualities and better conclusions. In a retrospective study published in 1999 by Sneed et al (1999) which contains 62 patients with one to four brain metastases indicated similar conclusions with our research. 43 of them received WBRT+SRS and 19 of them received SRS alone, the results shouwed that no diffreence of 1-year survival rate was observed between the two groups (71% vs. 79%), the new brain metastases was higher in the SRS group (28% vs. 69%, p=0.03).…”

Section: Discussionsupporting

confidence: 91%

Whole Brain Radiotherapy Combined with Stereotactic Radiotherapy Versus Stereotactic Radiotherapy Alone for Brain Metastases: a Meta-analysis

Duan¹,

Zeng²,

Yang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (2), 911-915 IntroductionCurrently, an increasing number of patients with cancer develop brain metastases, over 100,000 patients were diagnosed brain metastases each year in the United States (Stelzer et al., 2013). Brain metastases leave patients with a very poor prognosis, and the average survival was 1-2 months without treatment (Patil et al., 2012). The most common primary cancers metastasis to brain were lung cancer, renal carcinoma, breast cancer and esophagus cancer (Schouten et al., 2002). Patients with one metastatic lesion and well-controlled systemic disease can get good prognosis after surgery, however, the use of surgery in the treatment of brain metastases still remains controversial (Yaeger et al., 2013).In 1970s, the first option for brain metastases was the whole brain radiotherapy (WBRT), in recent years, the use of WBRT has decreased mainly because of the late toxicities are not self-limited and may have severe consequences that produce irreversible neurocognitive degeneration such as leukoencephalopathy, memory loss, emotional dysfunction, dementia, stupor, and coma (Abe et al., 2012;Mctyre et al., 2013

show abstract

Section: Discussionsupporting

confidence: 91%

Whole Brain Radiotherapy Combined with Stereotactic Radiotherapy Versus Stereotactic Radiotherapy Alone for Brain Metastases: a Meta-analysis

Duan¹,

Zeng²,

Yang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…They found no significant difference in the median overall survival time (P = 0, 42), while in terms of local and distant intracranial control patients receiving SRS plus WBRT had a better control rate (1-yr actuarial overall control rate 53,2% vs. 23,6; P \ 0,001) [20]. Several retrospective studies, despite the inherent biases, have shown that the omission of WBRT doesn't affect overall survival but has a negative impact on local and intracranial control [21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases

et al. 2008

View full text Add to dashboard Cite

Background The efficacy and toxicity of hypofractionated stereotactic radiotherapy (HSRT) in combination with whole brain radiotherapy (WBRT), for the treatment of 1-4 brain metastases, using a non invasive fixation of the skull, was investigated. Methods Between 04/2001 and 01/2006 30 patients with 44 brain metastases underwent irradiation. Every patient received WBRT (10 9 3 Gy); 41/44 lesions received HSRT boost with a median dose fraction of 6 Gy, the fractionation schemes were 3 9 6 Gy and 4 9 8 Gy; a median total dose of 18 Gy was delivered to the tumor isocenter. Results The median survival period was 9.15 months, the actuarial 1-year overall survival and freedom from new brain metastases were 36.6% and 87.9%, respectively; at univariate analysis Karnofsky Performance Status (KPS) was statistically significant (P = 0.05); the actuarial 1-year local control for the 41/44 lesions was 86.1%. No patient had acute or late complications. Conclusions HSRT as a concomitant boost during WBRT is a safe and well tolerated treatment for selected patients with brain metastases.

show abstract

“…Brain metastases may be treated with SRS alone or before or after whole brain RT. Retrospective [13][14][15][16] and prospective [17][18] studies showed that whole brain RT and SRS had no survival advantages over SRS alone. Phase III randomized trial on patients with one to three brain metastases (RTOG 9508) revealed that adding SRS to whole brain RT had improved functional autonomia and raised overall survival rates in inoperable tumors [19].…”

Section: Discussionmentioning

confidence: 99%

Retrospective Analysis Of Patients And Treatment Characteristics: Istanbul Cyberknife Coalition Data

Atalar¹,

Koçak²,

Ozseker³

et al. 2012

Cureus

View full text Add to dashboard Cite

Radiosurgery for brain metastases: is whole brain radiotherapy necessary?

Cited by 385 publications

References 23 publications

Whole Brain Radiotherapy Combined with Stereotactic Radiotherapy Versus Stereotactic Radiotherapy Alone for Brain Metastases: a Meta-analysis

Whole Brain Radiotherapy Combined with Stereotactic Radiotherapy Versus Stereotactic Radiotherapy Alone for Brain Metastases: a Meta-analysis

Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases

Retrospective Analysis Of Patients And Treatment Characteristics: Istanbul Cyberknife Coalition Data

Contact Info

Product

Resources

About